Alexis L.
- Country
- France
- Department
- Radiotherapy Departement
Research Overview
- Evaluation of Darolutamide and Stereotactic Dose-Escalated Radiotherapy in High-Risk Localized Prostate Cancer: A Phase III Randomized Trial
- (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer
Data & Insights
Has run more than one trial at 13 of 149 partner sites.
Specializations
Prostate Cancer Management
This investigator specializes in treating various stages of prostate cancer, with particular emphasis on biochemically recurrent cases and high-risk localized disease.
- Hormone-Sensitive Prostate Cancer
- Castration-Resistant Disease
- Oligometastatic Disease
The investigator focuses on implementing advanced therapeutic approaches for prostate cancer management and treatment optimization.
Advanced Imaging Applications
Integration of next-generation imaging techniques forms a core component of the investigator's clinical approach, particularly utilizing PSMA PET/CT scanning for disease monitoring and treatment planning.
- Functional Imaging Methods
- Metastasis Detection
- Treatment Response Assessment
Expertise includes using imaging technologies for precise disease staging and therapeutic response monitoring.
Therapeutic Interventions
The investigator employs diverse treatment modalities, including hormone therapy and stereotactic ablative radiotherapy, often in combination with novel therapeutic agents.
- Androgen Deprivation Therapy
- Targeted Radiation Approaches
- Immunotherapy Integration
Treatment strategies focus on personalized approaches for different disease presentations and risk levels.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.